SCHEMBL10244482

SCHEMBL10244482

CCN(CCNC(=O)OC)C(C)c1ccc(OC)c(CSc2nnnn2C)c1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.45
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
ALDH1A1 P00352 4/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TSHR P16473 1/20 0.41
MAPT P10636 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
PKM P14618 1/20 0.40
ATM Q13315 1/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL334665 0.86 ALDH1A1 (0.48) POLBHTTRAB9AALDH1A1L3MBTL1
SCHEMBL10282516 0.79 S1PR1 (0.37) ALDH1A1TSHRCYP1A2PKMLMNA
SCHEMBL10243935 0.79 PKM (0.45) ALDH1A1TSHRPKMLMNA
SCHEMBL10245320 0.76 S1PR1 (0.36) ALDH1A1TSHRCYP1A2LMNA
SCHEMBL10243957 0.76 L3MBTL1 (0.46) HTTALDH1A1L3MBTL1TSHRMAPT
SCHEMBL10244047 0.75 L3MBTL1 (0.47) HTTALDH1A1L3MBTL1TSHRMAPT
SCHEMBL10243900 0.74 S1PR1 (0.44) POLBHTTALDH1A1L3MBTL1MAPT
SCHEMBL334877 0.71 PKM (0.70) POLBALDH1A1L3MBTL1MAPTCYP1A2
SCHEMBL10243744 0.70 POLB (0.41) POLBHTTALDH1A1L3MBTL1MAPT
SCHEMBL10244037 0.70 CYP1A2 (0.46) RAB9AALDH1A1CYP1A2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 POLB 3348/4885HTT 868/4885RAB9A 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.